Welcome to Sphere Fluidics:

Sphere Fluidics Limited has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area. We have patented novel systems that enable ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes called picodroplets.  

Uniquely, these systems enable the study of different, large biomolecules that interact with or are secreted by single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology.

Sphere Fluidics' technology enables: study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains. Sphere Fluidics has established multiple commercial partnerships, won several waves of investment and together its Scientific Founders and the Company have received over £8 million in research and business funding to date.

The Company has the following USPs:

• One of the very few teams in the world with expertise in single cell analysis and picodroplet technology.
   
• Leading-edge, patented technology and proprietary know-how enables analysis and detection of single cells and their biomolecules.

• Extensive management experience in successfully commercialising innovative science and engineering.

• Expertise in a discovery platform with key applications that impacts multiple markets.

• Our novel "Cyto-Mine" process for single cell analysis and characterisation provides significant saving of time, resource and money compared to conventional workflows.

Sphere Fluidics can select, store and retrieve picodroplets containing a unique, single cell.